Neurofilament and glial fibrillary acidic protein in multiple sclerosis

Neurology

Volumn 63, Issue 9, 2004, Pages 1586-1590

  Norgren, N ^a   Sundstrom P ^b   Svenningsson, A ^b   Rosengren, L ^c   Stigbrand, T ^a   Gunnarsson, M ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN G; NEUROFILAMENT PROTEIN;

ADULT; ARTICLE; CELL COUNT; CEREBROSPINAL FLUID; CLINICAL STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROFILAMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE;

EID: 8644272511     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000142988.49341.D1     Document Type: Article

References (30)

1. Yabe JT, Pimenta A, Shea TB. Kinesin-mediated transport of neurofilament protein oligomers in growing axons. J Cell Sci 1999;112:3799-3814.
2. Shea TB, Flanagan LA. Kinesin, dynein and neurofilament transport. Trends Neurosci 2001;24:644-648.
3. Banik NL, Matzelle DC, Gantt-Wilford G, et al. Increased calpain content and progressive degradation of neurofilament protein in spinal cord injury. Brain Res 1997;752:301-306.
4. Schaecher K, Rocchini A, Dinkins J, et al. Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. J Neuroimmunol 2002;129:1-9.
5. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 1995;133:61-65.
6. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-404.
7. Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol 2002;122:132-139.
8. Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002;125:1462-1473.
9. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 1994;51:197-204.
10. Aurell A, Rosengren LE, Karlsson B, et al. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 1991;22:1254-1258.
11. Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-2018.
12. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003;987:25-31.
13. Norgren N, Karlsson JE, Rosengren L, Stigbrand T. Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics 2002;21:53-59.
14. Sundstrom P, Nystrom L, Forsgren L. Incidence (1988-97) and prevalence (1997) of multiple sclerosis in Vasterbotten County in northern Sweden. J Neurol Neurosurg Psychiatry 2003;74:29-32.
15. Poser CM. Onset symptoms of multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;58:253-254.
16. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
17. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
18. Poser S, Ritter G, Bauer HJ, et al. HLA-antigens and the prognosis of multiple sclerosis. J Neurol 1981;225:219-221.
19. Trojano M, Liguori M, Bosco Zimatore G, et al. Age-related disability in multiple sclerosis. Ann Neurol 2002;51:475-480.
20. Schreiber K, Otura AB, Ryder LP, et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002;8:295-298.
21. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-437.
22. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399.
23. Bitsch A, Schuchardt J, Bunkowski S, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000;123:1174-1183.
24. Evangelou N, Esiri MM, Smith S, et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000;47:391-395.
25. Lassmann H. Brain damage when multiple sclerosis is diagnosed clinically. Lancet 2003;361:1317-1318.
26. Lassmann H. Axonal injury in multiple sclerosis. J Neurol Neurosurg Psychiatry 2003;74:695-697.
27. Tsunoda I, Fujinami RS. Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination. Springer Semin Immunopathol 2002;24:105-125.
28. Bjartmar C, Kinkel RP, Kidd G, et al. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001;57:1248-1252.
29. Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-2212.
30. Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B. An acidic protein isolated from fibrous astrocytes. Brain Res 1971;28:351-354.